Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07818499 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma

Name: A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma — clinical trial record (NCT07818499)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorSichuan Baili Pharmaceutical Co., Ltd.

Started2026-09

View on ClinicalTrials.gov ↗

Sichuan Baili Pharmaceutical Co., Ltd.

135 trials monitored

See 14 trials at risk

Non-Hodgkin Lymphoma

1,512 trials monitored

See 79 trials at risk

DLBCL

648 trials monitored

See 32 trials at risk

This Phase Ib/II study is a clinical trial to explore the efficacy and safety of BL-M08D1 for injection in combination with immunochemotherapy in patients with diffuse large B-cell lymphoma.

Trial Details

NCT Number	NCT07818499
Lead Sponsor	Sichuan Baili Pharmaceutical Co., Ltd. Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions	Diffuse Large B-Cell Lymphoma
Enrollment	204 participants
Start Date	2026-09
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-09-14